Company News »

Company Profile for Aurinia Pharmaceuticals Inc.

Business Wire
Share on StockTwits
Published on

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently in the recruitment and enrollment phase of its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.

Company:

Aurinia Pharmaceuticals Inc.

Headquarters Address:

#1203 – 4464 Markham Street
Victoria, BC V8Z 7X8
Canada

Main Telephone:

250-708-4272

Website:

www.auriniapharma.com

Ticker/ISIN:

AUPH(NASDAQ)/CA05156V1022
AUP(TSX)/CA05156V1022

Type of Organization:

Public

Industry:

Pharmaceutical

Key Executives:

CEO: Stephen Zaruby

COO: Michael Martin

CFO: Dennis Bourgeault

Investor Relations

Contact:

Michael Martin

Phone:

250-708-4272

Email:

mmartin@auriniapharma.com

Share on StockTwits